Converting biology into clinical benefit: lessons learned from BRAF inhibitors

Jennifer McQuade; Michael A Davies

doi:10.2217/mmt.15.18

Converting biology into clinical benefit: lessons learned from BRAF inhibitors

Melanoma Manag. 2015;2(3):241-254. doi: 10.2217/mmt.15.18.

Authors

Jennifer McQuade¹, Michael A Davies¹

Affiliation

¹ The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Abstract

The identification and pharmacological targeting of activating BRAF mutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study of BRAF mutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.

Keywords: BRAF; NRAS; PI3K–AKT pathway; melanoma; resistance; targeted therapy.

Abstract

Grants and funding